Tr1X Inc. (pr. "Trix") is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases. The Company uses its proprietary platform for the generation of first-in-class cell therapy products aimed at rebalancing the immune system and restoring homeostasis, leading to long term tolerance. Tr1X is headquartered in La Jolla, CA.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $75M
Investors 1
| Date | Name | Website |
| - | Neva SGR | nevasgr.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.01.2024 | Series A | $75M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 19.01.2024 | Tr1X Raises $75M in Series A Funding | Tr1X, a San Diego, CA-based biotechnology company focused on engineering cures for immune and inflam... | finsmes.co... |
| 17.01.2024 | Tr1X Gets $75M In Series A | San Diego-based biotech developer Tr1X, a company developing therapies to treat autoimmune disease, ... | socaltech.... |
| - | Tr1x | “Engineered Tr1 cell therapies for autoimmune and inflammatory diseases.” | fastfounde... |